Study of OriCAR-017 for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new type of CAR-T cell therapy called OriCAR-017 for people with multiple myeloma that has come back or not responded to treatment. It is for patients who have already tried several treatments, including ones that target BCMA, and their last treatment stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have multiple myeloma that has come back or not responded to treatment.
- You have tried at least 3 prior treatments, and the last one stopped working.
- You have had a treatment that targets BCMA (like CAR-T or a bispecific antibody).
- You do not have active hepatitis B, hepatitis C, or HIV, and you have not had a stem cell transplant from a donor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This study tests an experimental cell therapy called CBG002 CAR-T for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses your own immune cells that are trained to find and attack myeloma cells with a protein called BCMA on their surface.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
This trial tests a new therapy called SYS6020 for people with multiple myeloma that has returned or not responded to treatment. The therapy targets a protein called BCMA on myeloma cells to try to shrink the cancer.
Hear when a new Neoplasms by Histologic Type trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.